{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"42.180","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2025","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"420,285,370","primaryexch":"HKEX","ric":"2591.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BVN1Y26","am":"19.18","iv":"","ew_strike":"","as":"41.840","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"41.500","registrar":"Tricor Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"200","update_time":"2025-09-26 10:38:37.0","lo52":"40.080","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Wang Qinghua","underlying_ric":"2591.HK","hi52":"74.000","issuer_name":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. - B - H Shs","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"41.000","mkt_cap":"17.58","f_aum_hkd":null,"ew_sub_per_to":"","ls":"41.840","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"+0.060","aum":"","issued_shares_class_B":null,"vo":"458.00","secondary_listing_flag":false,"listing_date":"15 Aug 2025","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. - B - H Shs","nm_s":"INNOGEN-B","sym":"2591","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.","op":"41.820","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 409, Building H<br/>Self-numbered Creative Bldg<br/>No. 2 Tengfei Second Street<br/>Huangpu Dist, Guangzhou, PRC","pc":"+0.14","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"41.780","isin":"CNE1000071Q7","moneyness":""}},"qid":"1758890329534"}
